Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging
Pulmonary infections caused by <i>Pseudomonas aeruginosa</i> (PA) represent the leading cause of pulmonary morbidity in adults with cystic fibrosis (CF). In addition to tobramycin, colistin, and aztreonam, levofloxacin has been approved in Europe to treat PA infections. Nevertheless, no...
Main Authors: | Carsten Schwarz, Claudio Procaccianti, Benjamin Mignot, Hosein Sadafi, Nicolas Schwenck, Xabier Murgia, Federico Bianco |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/12/2051 |
Similar Items
-
Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis
by: Carsten Schwarz, et al.
Published: (2022-08-01) -
The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics
by: Atqah AbdulWahab, et al.
Published: (2017-01-01) -
Nebulized levofloxacin for chronic Burkholderia cenocepacia pulmonary infection in cystic fibrosis: A case report
by: Renée VE. Dagenais, et al.
Published: (2022-01-01) -
Role of inhaled antibiotics in children and adolescents with cystic fibrosis: Experience from the tertiary care center
by: Danish Abdul Aziz, et al.
Published: (2022-01-01) -
Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives
by: Giovanni Taccetti, et al.
Published: (2021-03-01)